Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.

Cancer science - 1 Feb 2012

SongTao Qi, Lei Yu, Si Gui, YanQing Ding, HuiXia Han, XueLin Zhang, LanXiao Wu, Fei Yao

Abstract excerpt

Recent studies have shown that isocitrate dehydrogenase 1/2 (IDH1/2) mutations occur frequently in secondary glioblastoma. This study aimed to investigate their impact on temozolomide chemosensitivity and relationship with O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation in secondary glioblastoma. Searches for IDH1 and IDH2 mutations, 1p19q codeletion, MGMT promoter methylation, and p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to DNA Modification Methylases

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Temozolomide

Source

Identifiers

PMID: 22034964
DOI: 10.1111/j.1349-7006.2011.02134.x

Genes

MGMT
IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.PMID 22034964Read ↗

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.Semantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.Semantic proximity Read ↗

Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.Semantic proximity Read ↗

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Semantic proximity Read ↗

Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.Semantic proximity Read ↗

Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.Semantic proximity Read ↗

IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study.Semantic proximity Read ↗

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Semantic proximity Read ↗

Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.Semantic proximity Read ↗

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.Semantic proximity Read ↗

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.